Sanofi Antibiotic Takes Hit From FDA Advisers - WSJ.com
Ketek should no longer be marketed for sinusitis or bronchitis, because the drug's risks outweigh its benefits for those infections.
The drug has been linked to serious, though rare, cases of liver failure and damage, as well as severe risk to patients with myasthenia gravis, a neuromuscular disease. A few people taking Ketek have also suffered blurred vision and loss of consciousness
